This paper looks at the current state of the broad CNS market and reviews the key expectations for 2024. In it, we address Alzheimer’s disease, biomarkers, and advances in psychiatry in some detail. Finally, we look at the pain market and the evolving regulatory environment in shorter, “quick hit” fashion.
